| Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
|---|
ID: ALA5268281
Max Phase: Preclinical
Molecular Formula: C22H19F3N4O5S
Molecular Weight: 508.48
Associated Items:
Representations
Canonical SMILES: N#Cc1cc2c(nc1N1CCC(C(=O)NS(=O)(=O)Cc3ccc(C(F)(F)F)cc3)CC1)COC2=O
Standard InChI: InChI=1S/C22H19F3N4O5S/c23-22(24,25)16-3-1-13(2-4-16)12-35(32,33)28-20(30)14-5-7-29(8-6-14)19-15(10-26)9-17-18(27-19)11-34-21(17)31/h1-4,9,14H,5-8,11-12H2,(H,28,30)
Standard InChI Key: UUXFEHKFXNXZTG-UHFFFAOYSA-N
Associated Targets(Human)
Homo sapiens 32628 Activities
Molecule Features
| Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
| Molecule Type: | Topical: No | First In Class: No | Black Box: No |
| Chirality: No | Availability: No | Prodrug: No |
Drug Indications
| MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
|---|
Mechanisms of Action
| Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
|---|
Properties
| Molecular Weight: 508.48 | Molecular Weight (Monoisotopic): 508.1028 | AlogP: 2.51 | #Rotatable Bonds: 5 |
| Polar Surface Area: 129.46 | Molecular Species: ACID | HBA: 8 | HBD: 1 |
| #RO5 Violations: 1 | HBA (Lipinski): 9 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
| CX Acidic pKa: 3.97 | CX Basic pKa: 0.62 | CX LogP: 2.45 | CX LogD: 1.51 |
| Aromatic Rings: 2 | Heavy Atoms: 35 | QED Weighted: 0.61 | Np Likeness Score: -1.31 |
References
| 1. Kong D, Xue T, Guo B, Cheng J, Liu S, Wei J, Lu Z, Liu H, Gong G, Lan T, Hu W, Hu W, Yang Y.. (2019) Optimization of P2Y12 Antagonist Ethyl 6-(4-((Benzylsulfonyl)carbamoyl)piperidin-1-yl)-5-cyano-2-methylnicotinate (AZD1283) Led to the Discovery of an Oral Antiplatelet Agent with Improved Druglike Properties., 62 (6.0): [PMID:30843696] [10.1021/acs.jmedchem.8b01971] |
Source
Source(1):